CB2 Receptor Modulators for Selective Anti-Inflammatory Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic applications of cannabinoids are limited by their psychoactive effects, addiction potential, and inability to target specific medical conditions effectively, particularly in treating inflammation and pain without affecting the central nervous system.
Innovation Solution
Development of novel compounds that selectively modulate the CB2 receptor, acting as agonists, antagonists, or inverse agonists to treat inflammation and pain by administering therapeutic amounts, thereby avoiding the psychoactive effects associated with CB1 receptor modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cannabinoids (THC-based) are used for therapeutic purposes, then anti-emetic and appetite stimulant effects are achieved, but psychoactive effects (hallucination, addiction, dependence) occur
Solution Approach 1:
The patent applies segmentation by separating the cannabinoid receptor system into two distinct targets: CB1 receptors in the central nervous system (responsible for psychoactive effects) and CB2 receptors in the immune system (responsible for therapeutic effects). The invention develops compounds that selectively target only CB2 receptors, thereby segmenting the therapeutic action from psychoactive side effects and enabling reliable anti-inflammatory and analgesic treatment without hallucination or addiction.
2Reliability
If CB1 receptors are targeted for therapeutic effects, then central nervous system effects are achieved, but psychoactive effects and addiction potential increase
Solution Approach 1:
The patent applies the extraction principle by isolating and targeting only the CB2 receptor component of the cannabinoid system, extracting the therapeutic anti-inflammatory and analgesic functions while leaving behind the CB1-mediated psychoactive and addictive effects. The compounds are designed to bind selectively to CB2 receptors with high affinity, thereby extracting beneficial immune modulation without central nervous system penetration or addiction potential.
3Adaptability or versatility
If non-selective cannabinoid compounds are used, then broad therapeutic effects are achieved, but inability to target specific medical conditions effectively occurs
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures that exhibit selective affinity for CB2 receptors rather than non-selective binding to both CB1 and CB2. The chemical structure is optimized to match the binding pocket characteristics of CB2 receptors located in immune cells, thereby achieving precise targeting of inflammatory and pain pathways while maintaining the ability to treat specific medical conditions such as arthritis, multiple sclerosis, and chronic pain syndromes.
Data Source
AI summary
Compounds are provided which bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formulawherein, R1, R2, A, Y, X, Ar1 and Ar2 have the meanings given in the specification, and the preparation and use thereof. The compounds are valuable CB2 receptor modulators.